A polyethylene glycol monostearate (stPEG) micelle formulation successfully solubilized trans-resveratrol—a notoriously water-insoluble polyphenol—and demonstrated meaningful therapeutic effects in a lacrimal gland excision mouse model of dry eye disease (DED). The stPEG/Res formulation matched free resveratrol's antioxidant radical-scavenging capacity while maintaining comparable cytotoxicity profiles in human corneal epithelial cells. Critically, corneal inflammation and apoptosis were suppressed in vivo without any restoration of tear volume, isolating the drug's mechanism to direct tissue-level cytoprotection rather than secretomotor recovery.
Dry eye disease affects an estimated 344 million people globally, and current therapies—cyclosporine, lifitegrast, artificial tears—address either immune modulation or lubrication but rarely target oxidative stress and apoptosis simultaneously. Resveratrol's pleiotropic biology (SIRT1 activation, NF-κB suppression, Nrf2 upregulation) makes it mechanistically attractive here, but poor bioavailability has historically blocked topical ocular use. The stPEG micelle platform credibly solves the solubility barrier.
However, significant limitations temper enthusiasm: this is an acute surgical mouse model, not spontaneous DED; human corneal pharmacokinetics remain untested; and no dose-response data appear in the abstract. The finding is incremental-to-promising rather than paradigm-shifting—it validates a delivery vehicle concept that must now survive human tear-film dilution, blinking dynamics, and regulatory toxicology before clinical relevance can be claimed.
